Table 2.
Consequences of COVID-19.
| Totaln (%)N = 32 | Diagnosed by RT-PCRn (%)N = 14 | Diagnosed by clinical symptoms / radiological findingsn (%)N = 18 | |
|---|---|---|---|
| Died | |||
| Yes | 9 (28%) | 4 (29%) | 5 (28%) |
| No | 23 (72%) | 10 (71%) | 13 (72%) |
| Hospitalised | |||
| Yes | 19 (59%) | 11 (79%) | 8 (44%) |
| No | 13 (41%) | 3 (21%) | 10 (56%) |
| Required oxygen | |||
| Yes | 13 (41%) | 7 (50%) | 6 (33%) |
| No | 19 (59%) | 7 (50%) | 12 (67%) |
| Required NIV | |||
| Yes | 5 (16%) | 3 (21%) | 2 (11%) |
| No | 27 (84%) | 11 (79%) | 16 (89%) |
| HDU/ICU admission | |||
| No | 26 (81%) | 10 (71%) | 17 (94%) |
| Yes | 6 (19%) | 4 (29%) | 2 (12%) |
| • ICU • HDU |
1 (3%) 5 (16%) |
0 (0%) 4 (29%) |
1 (6%) 1 (6%) |
| Complications | |||
| Pneumonia | 9 (28%) | 6 (43%) | 3 (17%) |
| ARDS | 3 (9%) | 1 (7%) | 2 (11%) |
| Sepsis | 4 (12%) | 2 (14%) | 2 (11%) |
| Arrhythmia | 3 (9%) | 1 (7%) | 2 (11%) |
| Treatment received | |||
| Antibiotics | 21 (66%) | 9 (64%) | 12 (67%) |
| Antivirals | 1 (3%) | 1 (7%) | 0 (0%) |
| Antifungals | 2 (6%) | 0 (0%) | 2 (11%) |
| Steroids | 10 (31%) | 3 (21%) | 7 (39%) |
| Home oxygen on discharge | |||
| Yes | 2 (6%) | 1 (7%) | 1 (6%) |
| No | 30 (94%) | 13 (93%) | 17 (94%) |
| Treatment interruption | |||
| No | 15 (47%) | 4 (29%) | 11 (61%) |
| Yes | 17 (53%) | 10 (71%) | 7 (39%) |
| • Delay • Cessation |
9 (28%) 8 (25%) |
6 (43%) 4 (29%) |
3 (17%) 4 (22%) |
Abbreviations: ARDS: acute respiratory distress syndrome; HDU: high dependency unit; ICU: intensive care unit; NIV: non-invasive ventilation; RT-PCR: reverse transcriptase polymerase chain reaction.